483
Richard E. Ringel, M.D.FDA 483 - Richard E. Ringel, M.D. - December 17, 2015
Record Details
An FDA inspection of Richard E. Ringel, M.D. in Baltimore, MD, from December 14-17, 2015, revealed significant deviations from an investigational plan and study protocol. The firm failed to properly record adverse events for study subjects and did not maintain adequate subject accountability, including follow-up for missed visits and documentation for subjects lost to follow-up. These findings indicate serious issues in the conduct and oversight of clinical investigations.
Open in Dashboard
ID · 9d7e6053-24c3-42c0-8707-0626d05a0d5d